Enhanced circulating PCSK9 concentration by berberine through SREBP-2 pathway in high fat diet-fed rats

Short-Term Impact of Low-Dose Atorvastatin on Serum Proprotein Convertase Subtilisin/Kexin Type 9

(2013) Yuan-Lin Guo et al.   CLINICAL DRUG INVESTIGATION

Molecular characterization of proprotein convertase subtilisin/kexin type 9-mediated degradation of the LDLR

(2012) Yan Wang et al.   JOURNAL OF LIPID RESEARCH

Clinical aspects of PCSK9

(2011) Bertrand Cariou et al.   ATHEROSCLEROSIS

Strong induction of PCSK9 gene expression through HNF1α and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters

(2010) Bin Dong et al.   JOURNAL OF LIPID RESEARCH

High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol

(2010) Greg Welder et al.   JOURNAL OF LIPID RESEARCH

Berberine inhibits adipogenesis in high-fat diet-induced obesity mice

(2009) Yueshan Hu et al.   FITOTERAPIA

Hepatocyte Nuclear Factor 1α Plays a Critical Role inPCSK9Gene Transcription and Regulation by the Natural Hypocholesterolemic Compound Berberine

(2009) Hai Li et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Antagonism of Secreted PCSK9 Increases Low Density Lipoprotein Receptor Expression in HepG2 Cells

(2009) Markey C. McNutt et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Berberine decreases PCSK9 expression in HepG2 cells

(2008) Jamie Cameron et al.   ATHEROSCLEROSIS